Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs 22nd Century Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while 22nd Century Group Inc trades at $4.1 (market cap $1.46M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 27321.9× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| ALNY | XXII | |
|---|---|---|
Market Cap | $39.89B | $1.46M |
Sector | Health | Technology |
52-Week High | $491.22 | $1.85K |
52-Week Low | $278.09 | $3.90 |
Enterprise Value | $38.15B | -$6.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $4.23, down 2.08% on the day, amid a bearish technical signal. The company's financials show deep losses with a net income margin of -65.76% and negative ROE of -130.19% for 2026. Recent news highlights expansion of its VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. Analyst consensus is 75% buy, but earnings misses in Q4 2025 and Q1 2026 raise execution concerns.
The outlook hinges on VLN's commercial success and FDA regulatory pathway. High cash burn necessitates ongoing financing, evident in 2026's $17M financing inflow. Risks include persistent unprofitability, competitive pressures, and reliance on tobacco harm reduction narrative. Upside depends on revenue scaling and margin improvement from new retail launches.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
